Lukas Hainz

Lukas Hainz

Biopharma Innovation Specialist
Lukas Hainz specializes in biopharmaceutical research and development. He unpacks research from clinical trials and explores regulatory affairs implications on the pharmaceutical industry, focusing on innovative therapies and patent development.
How Are U.S. Cardiovascular Device Markets Evolving?
Management & Administration How Are U.S. Cardiovascular Device Markets Evolving?

The cardiovascular device market in the United States is marked by fast-paced developments, driven by significant epidemiological and technological factors that profoundly influence the healthcare industry. As cardiovascular diseases continue to be the leading health concern in the U.S., the demand

Is Public Sector Abandoning Cancer Research Funding?
Tech & Innovation Is Public Sector Abandoning Cancer Research Funding?

In an era where the fight against cancer is more critical than ever, the proposed drastic 40% cut in funding for the National Cancer Institute (NCI) by the Biden administration poses unsettling questions about the United States' commitment to combating this relentless disease. This significant

Why Digital Health Struggles to Scale And How to Change That
Editorial Why Digital Health Struggles to Scale And How to Change That

Healthcare systems worldwide are facing significant challenges. The aging population, rising chronic illnesses, workforce shortages, and increasing costs force systems to rethink how they deliver care. The potential of digital health—using technology to enhance care delivery, improve patient

Nabla Expands Healthcare AI Solutions with $70 Million Funding
Tech & Innovation Nabla Expands Healthcare AI Solutions with $70 Million Funding

Imagine a world where a healthcare professional's day is not consumed by paperwork and administrative tasks, but rather focused on patient care. With the astonishing pace at which artificial intelligence is evolving, this scenario is swiftly transitioning from a dream to reality. Today, AI is not

HIV Activists Fight Against Federal Funding Cuts in Mississippi
Clinical & Pharma HIV Activists Fight Against Federal Funding Cuts in Mississippi

The ongoing battle against HIV in the United States faces significant challenges as federal funding cuts threaten vital prevention and treatment programs. In Mississippi, where health disparities are particularly pronounced, dedicated activists like Cedric Sturdevant have risen to the occasion,

Why Do 90% of Health Startups Hit Revenue Walls?
Tech & Innovation Why Do 90% of Health Startups Hit Revenue Walls?

The health innovation sector continues to witness an influx of startups, each eager to carve a niche in an ever-evolving industry characterized by technological advancements and innovative solutions. Despite the optimism driving the establishment of new ventures, an overwhelming majority face the

Modernizing Medicaid: Texting Reform Sparks Legislative Debate
Management & Administration Modernizing Medicaid: Texting Reform Sparks Legislative Debate

James Maitland is a leading voice in the intersection of healthcare and technology, with a remarkable ability to translate complex robotics and IoT applications into practical solutions for medical care advancement. Here, he shares insights on the pressing issue of updating managed care

Trend Analysis: AI Model Validation in Healthcare
Tech & Innovation Trend Analysis: AI Model Validation in Healthcare

In an era where precision and reliability in healthcare are paramount, the rise of artificial intelligence (AI) model validation is reshaping the medical landscape. This trend spotlights the transition from theoretical AI applications to practical implementations within the sector, promising

Trend Analysis: Health Budget Restructuring
Tech & Innovation Trend Analysis: Health Budget Restructuring

A seismic shift in the federal budget allocation for health services has been proposed, threatening to redefine vital aspects of public health infrastructure. The Trump administration's blueprint for a 25% cut in discretionary funding for the Department of Health and Human Services (HHS) by 2026

BioNTech To Acquire CureVac, Boosting mRNA Cancer Therapies
Clinical & Pharma BioNTech To Acquire CureVac, Boosting mRNA Cancer Therapies

BioNTech, a leading force in the global pharmaceuticals industry, has embarked on a strategic acquisition of CureVac to solidify its position in mRNA-based cancer therapeutics. With this acquisition, the company looks to expand its capabilities beyond the notable success achieved with the COVID-19

Loading
Latest Articles

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later